Compare PCRX & PXED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | PXED |
|---|---|---|
| Founded | 2006 | 1976 |
| Country | United States | United States |
| Employees | N/A | 3400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2010 | N/A |
| Metric | PCRX | PXED |
|---|---|---|
| Price | $23.50 | $30.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $30.25 | ★ $44.29 |
| AVG Volume (30 Days) | ★ 516.5K | 71.6K |
| Earning Date | 04-30-2026 | 04-07-2026 |
| Dividend Yield | N/A | ★ 3.07% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | $3.85 |
| Revenue Next Year | $8.54 | $4.49 |
| P/E Ratio | $336.29 | ★ $11.20 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $23.52 |
| 52 Week High | $27.64 | $38.19 |
| Indicator | PCRX | PXED |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 53.45 |
| Support Level | $22.13 | $28.40 |
| Resistance Level | $24.20 | $30.85 |
| Average True Range (ATR) | 1.02 | 1.37 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 42.93 | 57.47 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.